// COMPANY
Alentis Therapeutics
SECTOR BIOTECHMENTIONS 1LAST SEEN OCTOBER 6, 2026
Discussed in
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
m_and_a·PitchBook News·OCTOBER 6, 2026
“CSL agreed to a $1.6 billion deal with OrbiMed-backed Alentis Therapeutics to develop a drug for rare kidney and liver diseases.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.